hydroxychloroquine has been researched along with Cancer of the Thyroid in 1 studies
Hydroxychloroquine: A chemotherapeutic agent that acts against erythrocytic forms of malarial parasites. Hydroxychloroquine appears to concentrate in food vacuoles of affected protozoa. It inhibits plasmodial heme polymerase. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p970)
hydroxychloroquine : An aminoquinoline that is chloroquine in which one of the N-ethyl groups is hydroxylated at position 2. An antimalarial with properties similar to chloroquine that acts against erythrocytic forms of malarial parasites, it is mainly used as the sulfate salt for the treatment of lupus erythematosus, rheumatoid arthritis, and light-sensitive skin eruptions.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Patients with Graves' disease who remain hyperthyroid under the treatment of antithyroid drugs (ATD) or cannot tolerate ATD usually receive radioactive iodine (RAI) to control disease activity." | 8.31 | Predictors of Prolonged Euthyroidism After Radioactive Iodine Treatment for Graves' Disease: A Pilot Study. ( Chen, KH; Chen, TC; Hu, FC; Lu, JY; Shih, SR; Wen, FY; Wu, WC, 2023) |
| "Patients with Graves' disease who remain hyperthyroid under the treatment of antithyroid drugs (ATD) or cannot tolerate ATD usually receive radioactive iodine (RAI) to control disease activity." | 4.31 | Predictors of Prolonged Euthyroidism After Radioactive Iodine Treatment for Graves' Disease: A Pilot Study. ( Chen, KH; Chen, TC; Hu, FC; Lu, JY; Shih, SR; Wen, FY; Wu, WC, 2023) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Lu, JY | 3 |
| Chen, KH | 3 |
| Shih, SR | 3 |
| Wen, FY | 3 |
| Wu, WC | 3 |
| Chen, TC | 3 |
| Hu, FC | 3 |
1 other study available for hydroxychloroquine and Cancer of the Thyroid
| Article | Year |
|---|---|
Predictors of Prolonged Euthyroidism After Radioactive Iodine Treatment for Graves' Disease: A Pilot Study.
Topics: Antithyroid Agents; Child, Preschool; Graves Disease; Humans; Hydroxychloroquine; Hyperthyroidism; I | 2023 |
Predictors of Prolonged Euthyroidism After Radioactive Iodine Treatment for Graves' Disease: A Pilot Study.
Topics: Antithyroid Agents; Child, Preschool; Graves Disease; Humans; Hydroxychloroquine; Hyperthyroidism; I | 2023 |
Predictors of Prolonged Euthyroidism After Radioactive Iodine Treatment for Graves' Disease: A Pilot Study.
Topics: Antithyroid Agents; Child, Preschool; Graves Disease; Humans; Hydroxychloroquine; Hyperthyroidism; I | 2023 |
Predictors of Prolonged Euthyroidism After Radioactive Iodine Treatment for Graves' Disease: A Pilot Study.
Topics: Antithyroid Agents; Child, Preschool; Graves Disease; Humans; Hydroxychloroquine; Hyperthyroidism; I | 2023 |
Predictors of Prolonged Euthyroidism After Radioactive Iodine Treatment for Graves' Disease: A Pilot Study.
Topics: Antithyroid Agents; Child, Preschool; Graves Disease; Humans; Hydroxychloroquine; Hyperthyroidism; I | 2023 |
Predictors of Prolonged Euthyroidism After Radioactive Iodine Treatment for Graves' Disease: A Pilot Study.
Topics: Antithyroid Agents; Child, Preschool; Graves Disease; Humans; Hydroxychloroquine; Hyperthyroidism; I | 2023 |
Predictors of Prolonged Euthyroidism After Radioactive Iodine Treatment for Graves' Disease: A Pilot Study.
Topics: Antithyroid Agents; Child, Preschool; Graves Disease; Humans; Hydroxychloroquine; Hyperthyroidism; I | 2023 |
Predictors of Prolonged Euthyroidism After Radioactive Iodine Treatment for Graves' Disease: A Pilot Study.
Topics: Antithyroid Agents; Child, Preschool; Graves Disease; Humans; Hydroxychloroquine; Hyperthyroidism; I | 2023 |
Predictors of Prolonged Euthyroidism After Radioactive Iodine Treatment for Graves' Disease: A Pilot Study.
Topics: Antithyroid Agents; Child, Preschool; Graves Disease; Humans; Hydroxychloroquine; Hyperthyroidism; I | 2023 |